<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511535</url>
  </required_header>
  <id_info>
    <org_study_id>TBE_1.1</org_study_id>
    <nct_id>NCT02511535</nct_id>
  </id_info>
  <brief_title>TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients</brief_title>
  <official_title>TBE (Tick-borne Encephalitis ) Vaccination in Allergic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allergic patients especially those undergoing de-sensitization treatment have an altered
      immune responsiveness. The investigators aim to find out whether this influences immune
      responses to primary and booster vaccinations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allergic patients generally have an altered immunologic profile (Th2 bias), and allergic
      individuals undergoing de-sensitization treatment display an increased production of immune
      suppressive cytokines. The investigators measure humoral and cellular immune responses to
      routine vaccination (Tick-borne Encephalitis [TBE] booster) in allergic patients with and
      without de-sensitization treatment to determine whether allergy negatively influences vaccine
      induced immune responses and protection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Humoral TBE Immunity</measure>
    <time_frame>one month after booster vaccination</time_frame>
    <description>Geometric mean titers of TBE specific neutralizing Abs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular Immune Response - Cytokine Production</measure>
    <time_frame>before (day 0) and 1week after booster vaccination</time_frame>
    <description>cytokine production of antigen-specifically re-stimulated PMBC, IL-2 (interleukin 2) IFN g (interferon gamma) IL-10 (interleukin 10) IL-5 (interleukin 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular Immune Response - Lymphocyte Subpopulations</measure>
    <time_frame>before (day 0) and 1week after booster vaccination</time_frame>
    <description>analyses of naive, memory and regulatory sub-populations of B- and T-lymphocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TBE Titer Course</measure>
    <time_frame>before (day 0) until 6 months after booster vaccination</time_frame>
    <description>Fold Change in TBE Specific Neutralizing Antibodies from day 0 (before booster) and one week, one month and 6 months after booster vaccination</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Vaccine Responsiveness in Allergy</condition>
  <condition>Vaccine Responsiveness During Allergy De-sensitization Treatment</condition>
  <arm_group>
    <arm_group_label>Allergic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allergic patients receive TBE booster vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergic patients with de-sensitization treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allergic patients with de-sensitization treatment receive TBE booster vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy controls receive TBE booster vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TBE booster vaccination</intervention_name>
    <arm_group_label>Allergic patients</arm_group_label>
    <arm_group_label>Allergic patients with de-sensitization treatment</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <other_name>Vaccine: FSME-Immun® (Fruehsommer-Meningoencephalitis)</other_name>
    <other_name>One dose (0.5 ml) contains:</other_name>
    <other_name>2.4 micrograms Tick-Borne Encephalitis Virus ( strain Neudoerfl),</other_name>
    <other_name>adsorbed on aluminium oxide, hydrated (0.35 milligrams Al3+)</other_name>
    <other_name>Manufacturer: Baxter Innovations GmbH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  completed primary TBE immunization + at least one booster immunization

          -  adults of both sexes between 18 and 60 years of age

          -  willingness to sign written informed consent form

        Exclusion Criteria:

          -  age &lt; 18 and &gt; 60 years

          -  prior TBE infection

          -  Hepatitis A vaccination

          -  pregnancy and breast feeding

          -  acute infection on day of inclusion (day 0), body temperature &gt;37,9°C

          -  concomitant medications: systemic cortisone therapy, chemotherapy, immunosuppressive
             therapy 4 weeks prior to or during study

          -  administration of other vaccines 4 weeks before/after TBE vaccination

          -  planned surgery within 2 weeks before/after TBE vaccination

          -  Start of de-sensitization and the first 4 weeks of allergen dose escalation

          -  any contraindication to administration of FSME-Immun® vaccine according to
             manufacturer's instructions

          -  history of malignant disease within the last 5 years

          -  autoimmune diseases

          -  drug addictions

          -  plasma donors

          -  receipt of blood transfusions or immuno globulins within 3 month before study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ursula Wiedermann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Vienna, Institute of Specific Prophylaxis and Tropical Medicine</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S0264410X18304547?via%3Dihub</url>
    <description>Science Direct, Vaccine, Volume 36, Issue 20, 11 May 2018, Pages 2816-2824</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 23, 2015</study_first_submitted>
  <study_first_submitted_qc>July 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <results_first_submitted>July 8, 2019</results_first_submitted>
  <results_first_submitted_qc>October 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2019</results_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Univ. Prof. Dr. Ursula Wiedermann</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr. Ursula Wiedermann, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis, Tick-Borne</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Allergic Patients</title>
          <description>Allergic patients receive TBE booster vaccination
TBE booster vaccination</description>
        </group>
        <group group_id="P2">
          <title>Allergic Patients With De-sensitization Treatment</title>
          <description>Allergic patients with de-sensitization treatment receive TBE booster vaccination
TBE booster vaccination</description>
        </group>
        <group group_id="P3">
          <title>Healthy Controls</title>
          <description>Healthy controls receive TBE booster vaccination
TBE booster vaccination</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Allergic Patients</title>
          <description>Allergic patients receive TBE booster vaccination</description>
        </group>
        <group group_id="B2">
          <title>Allergic Patients With De-sensitization Treatment</title>
          <description>Allergic patients with de-sensitization treatment receive TBE booster vaccination</description>
        </group>
        <group group_id="B3">
          <title>Healthy Controls</title>
          <description>Healthy controls receive TBE booster vaccination</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Humoral TBE Immunity</title>
        <description>Geometric mean titers of TBE specific neutralizing Abs</description>
        <time_frame>one month after booster vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allergic Patients</title>
            <description>Allergic patients receive TBE booster vaccination</description>
          </group>
          <group group_id="O2">
            <title>Allergic Patients With De-sensitization Treatment</title>
            <description>Allergic patients with de-sensitization treatment receive TBE booster vaccination</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>Healthy controls receive TBE booster vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Humoral TBE Immunity</title>
          <description>Geometric mean titers of TBE specific neutralizing Abs</description>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317.90" lower_limit="238.70" upper_limit="423.30"/>
                    <measurement group_id="O2" value="250.10" lower_limit="143.90" upper_limit="434.40"/>
                    <measurement group_id="O3" value="282.20" lower_limit="210.60" upper_limit="378.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cellular Immune Response - Cytokine Production</title>
        <description>cytokine production of antigen-specifically re-stimulated PMBC, IL-2 (interleukin 2) IFN g (interferon gamma) IL-10 (interleukin 10) IL-5 (interleukin 5)</description>
        <time_frame>before (day 0) and 1week after booster vaccination</time_frame>
        <population>the missing cytokine concentrations were not used for calculation because of invalid positive controls (due to poor PBMC [peripheral blood mononuclear cell] viability)</population>
        <group_list>
          <group group_id="O1">
            <title>Allergic Patients</title>
            <description>Allergic patients receive TBE booster vaccination</description>
          </group>
          <group group_id="O2">
            <title>Allergic Patients With De-sensitization Treatment</title>
            <description>Allergic patients with de-sensitization treatment receive TBE booster vaccination</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>Healthy controls receive TBE booster vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Cellular Immune Response - Cytokine Production</title>
          <description>cytokine production of antigen-specifically re-stimulated PMBC, IL-2 (interleukin 2) IFN g (interferon gamma) IL-10 (interleukin 10) IL-5 (interleukin 5)</description>
          <population>the missing cytokine concentrations were not used for calculation because of invalid positive controls (due to poor PBMC [peripheral blood mononuclear cell] viability)</population>
          <units>pg/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IFNg before vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.85" lower_limit="25.86" upper_limit="55.39"/>
                    <measurement group_id="O2" value="42.54" lower_limit="23.36" upper_limit="77.49"/>
                    <measurement group_id="O3" value="38.91" lower_limit="25.13" upper_limit="59.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNg 1 week post vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.19" lower_limit="37.61" upper_limit="78.08"/>
                    <measurement group_id="O2" value="59.45" lower_limit="32.67" upper_limit="108.17"/>
                    <measurement group_id="O3" value="77.27" lower_limit="52.26" upper_limit="114.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 before vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.21" lower_limit="25.90" upper_limit="47.86"/>
                    <measurement group_id="O2" value="38.86" lower_limit="23.75" upper_limit="63.58"/>
                    <measurement group_id="O3" value="30.28" lower_limit="21.15" upper_limit="43.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 one week post vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.90" lower_limit="36.60" upper_limit="65.33"/>
                    <measurement group_id="O2" value="52.13" lower_limit="37.00" upper_limit="73.44"/>
                    <measurement group_id="O3" value="52.28" lower_limit="36.47" upper_limit="74.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 before vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.62" lower_limit="36.54" upper_limit="75.78"/>
                    <measurement group_id="O2" value="35.41" lower_limit="21.25" upper_limit="59.02"/>
                    <measurement group_id="O3" value="37.20" lower_limit="24.43" upper_limit="56.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 one week post vacc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.80" lower_limit="37.03" upper_limit="78.18"/>
                    <measurement group_id="O2" value="37.11" lower_limit="24.44" upper_limit="56.34"/>
                    <measurement group_id="O3" value="51.07" lower_limit="34.57" upper_limit="75.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-5 before vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" lower_limit="1.81" upper_limit="2.40"/>
                    <measurement group_id="O2" value="1.85" lower_limit="1.85" upper_limit="1.85"/>
                    <measurement group_id="O3" value="2.04" lower_limit="1.87" upper_limit="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-5 one week post vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" lower_limit="2.32" upper_limit="3.77"/>
                    <measurement group_id="O2" value="1.87" lower_limit="1.84" upper_limit="1.90"/>
                    <measurement group_id="O3" value="2.85" lower_limit="2.23" upper_limit="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cellular Immune Response - Lymphocyte Subpopulations</title>
        <description>analyses of naive, memory and regulatory sub-populations of B- and T-lymphocytes</description>
        <time_frame>before (day 0) and 1week after booster vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allergic Patients</title>
            <description>Allergic patients receive TBE booster vaccination</description>
          </group>
          <group group_id="O2">
            <title>Allergic Patients With De-sensitization Treatment</title>
            <description>Allergic patients with de-sensitization treatment receive TBE booster vaccination</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>Healthy controls receive TBE booster vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Cellular Immune Response - Lymphocyte Subpopulations</title>
          <description>analyses of naive, memory and regulatory sub-populations of B- and T-lymphocytes</description>
          <units>percent of total lymphocytes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T cells (CD3 +) at day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" lower_limit="66.9" upper_limit="71.8"/>
                    <measurement group_id="O2" value="73.7" lower_limit="70.9" upper_limit="76.5"/>
                    <measurement group_id="O3" value="68.2" lower_limit="65.5" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T cells (CD3 +) 1 week after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.7" lower_limit="66.1" upper_limit="71.2"/>
                    <measurement group_id="O2" value="74.7" lower_limit="72.4" upper_limit="77.1"/>
                    <measurement group_id="O3" value="70.6" lower_limit="68.3" upper_limit="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B cells (CD19 +) at day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.63" lower_limit="6.67" upper_limit="8.57"/>
                    <measurement group_id="O2" value="7.01" lower_limit="6.04" upper_limit="7.98"/>
                    <measurement group_id="O3" value="7.11" lower_limit="6.34" upper_limit="7.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B cells (CD19 +) 1 week after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.22" lower_limit="6.33" upper_limit="8.11"/>
                    <measurement group_id="O2" value="6.34" lower_limit="5.34" upper_limit="7.34"/>
                    <measurement group_id="O3" value="6.39" lower_limit="5.78" upper_limit="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T helper cells (CD4 +) at day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" lower_limit="39.9" upper_limit="44.6"/>
                    <measurement group_id="O2" value="49.1" lower_limit="45.5" upper_limit="52.4"/>
                    <measurement group_id="O3" value="41.6" lower_limit="38.7" upper_limit="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T helper cells (CD4 +) 1 week after booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" lower_limit="40.4" upper_limit="45.0"/>
                    <measurement group_id="O2" value="50.5" lower_limit="47.6" upper_limit="53.4"/>
                    <measurement group_id="O3" value="43.0" lower_limit="40.1" upper_limit="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cytotoxic T cells (CD8 +) at day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" lower_limit="19.8" upper_limit="23.3"/>
                    <measurement group_id="O2" value="20.3" lower_limit="17.0" upper_limit="23.4"/>
                    <measurement group_id="O3" value="20.6" lower_limit="18.4" upper_limit="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cytotoxic T cells (CD8 +) 1 week after booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" lower_limit="19.3" upper_limit="22.6"/>
                    <measurement group_id="O2" value="20.7" lower_limit="17.5" upper_limit="23.8"/>
                    <measurement group_id="O3" value="21.2" lower_limit="19.0" upper_limit="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tregs (CD4+ FOXP3+) at day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.65" lower_limit="4.20" upper_limit="5.13"/>
                    <measurement group_id="O2" value="5.36" lower_limit="4.61" upper_limit="6.16"/>
                    <measurement group_id="O3" value="4.49" lower_limit="4.10" upper_limit="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tregs (CD4+ FOXP3+) 1 week after booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.54" lower_limit="4.10" upper_limit="5.01"/>
                    <measurement group_id="O2" value="5.60" lower_limit="4.93" upper_limit="6.30"/>
                    <measurement group_id="O3" value="4.21" lower_limit="3.84" upper_limit="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TBE Titer Course</title>
        <description>Fold Change in TBE Specific Neutralizing Antibodies from day 0 (before booster) and one week, one month and 6 months after booster vaccination</description>
        <time_frame>before (day 0) until 6 months after booster vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allergic Patients</title>
            <description>Allergic patients receive TBE booster vaccination</description>
          </group>
          <group group_id="O2">
            <title>Allergic Patients With De-sensitization Treatment</title>
            <description>Allergic patients with de-sensitization treatment receive TBE booster vaccination</description>
          </group>
          <group group_id="O3">
            <title>Healthy Controls</title>
            <description>Healthy controls receive TBE booster vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>TBE Titer Course</title>
          <description>Fold Change in TBE Specific Neutralizing Antibodies from day 0 (before booster) and one week, one month and 6 months after booster vaccination</description>
          <units>fold change from d0 (before booster)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>fold change 1 week after booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" lower_limit="1.23" upper_limit="1.73"/>
                    <measurement group_id="O2" value="1.80" lower_limit="1.36" upper_limit="2.37"/>
                    <measurement group_id="O3" value="1.79" lower_limit="1.50" upper_limit="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fold change 4 weeks after booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" lower_limit="2.43" upper_limit="3.77"/>
                    <measurement group_id="O2" value="3.01" lower_limit="2.05" upper_limit="4.41"/>
                    <measurement group_id="O3" value="2.56" lower_limit="2.09" upper_limit="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fold change 6 month after booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" lower_limit="1.54" upper_limit="2.46"/>
                    <measurement group_id="O2" value="2.53" lower_limit="1.81" upper_limit="3.54"/>
                    <measurement group_id="O3" value="1.79" lower_limit="1.41" upper_limit="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Allergic Patients</title>
          <description>Allergic patients receive TBE booster vaccination</description>
        </group>
        <group group_id="E2">
          <title>Allergic Patients With De-sensitization Treatment</title>
          <description>Allergic patients with de-sensitization treatment receive TBE booster vaccination</description>
        </group>
        <group group_id="E3">
          <title>Healthy Controls</title>
          <description>Healthy controls receive TBE booster vaccination</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>vaccine reactogenicity</sub_title>
                <description>local reactions to TBE vaccination</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Erika Garner-Spitzer, PhD</name_or_title>
      <organization>Med Uni Wien, Institut für Spezifische Prophylaxe und Tropenmedizin</organization>
      <phone>0043 1 40160 ext 38255</phone>
      <email>erika.garner-spitzer@meduniwien.ac.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

